Rosen Quoted on FDA Guidance

12 October 2011 Genetic Engineering & Biotechnology News News

Foley Partner David Rosen was quoted in an article that appeared in Genetic Engineering & Biotechnology News on October 12, 2011 titled "Extent of Feedback on RUO/IUO In Vitro Dx Draft Guidance Means Changes Not Expected Soon." Rosen discusses draft guidance proposed by the FDA concerning the labeling of in vitro diagnostic (IVD) products marked "for research use only" (RUO) and "for investigational use only" (IUO). He states that some companies are concerned about what products they can sell as RUO/IUO tests and what they cannot under the FDA’s draft guidelines. Rosen recognizes the need for research, but notes that it is also important to ensure that people do not rely on tests that are not verified and validated.

Related Services


Text Messages, EDiscovery, and the New Threat to Privacy
21 November 2019
CMS Proposes Enhanced Scrutiny over Medicaid Supplemental Payments
20 November 2019
Health Care Law Today
The Purpose of a Corporation
November 2019
Legal News: Business Law
Should This Be a "Mobility" Industry Blog?
19 November 2019
Dashboard Insights
PATH Summit 2019
18-20 December 2019
Arlington, VA
Madison CLE Days
18-19 December 2019
Madison, WI
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
HFMA MA-RI Annual Compliance Update
12 December 2019
Boston, MA